Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8778569 | European Urology | 2018 | 10 Pages |
Abstract
In this report, we performed a systematic review of the literature to determine the benefit and harm of adding hormone therapy to salvage radiotherapy (SRT) for recurrent prostate cancer. We found that the benefit of hormone therapy varied by important prognostic factors, including pre-SRT prostate-specific antigen, Gleason grade, and surgical margin status. Our group then developed a framework on how best to utilize hormone therapy with SRT.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, Daniel W. Lin, Phuoc T. Tran, Todd M. Morgan, Emmanuel S. Antonarakis, Paul L. Nguyen, Charles J. Ryan, Howard M. Sandler, Matthew R. Cooperberg, Edwin Posadas, Felix Y. Feng,